Item 8.01 Other Events.

On October 7, 2021, ORIC Pharmaceuticals, Inc. (the "Company") issued a press release announcing (i) initial clinical data from its ongoing Phase 1b study evaluating ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide, in patients with metastatic prostate cancer progressing on enzalutamide and (ii) preclinical data on ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations. A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit No.   Description

99.1            Press Release dated October 7, 2021.

104           Cover Page Interactive Data File (formatted as Inline XBRL).




                                      -2-

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses